Saturday, September 18, 2021

Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy




Gilead Sciences has revealed new, four-year data from two Phase III studies evaluating Biktarvy for the treatment of HIV-1 in treatment-naïve adults.

In the two studies – Study 1489 and Study 1490 – 98% of participants who started treatment with Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) achieved and maintained an undetectable viral load through four years of follow-up.

High efficacy and durable viral suppression were also observed in participants who switched to Biktarvy from dolutegravir-containing triple therapy for the 48-week open-label extension periods.

Gilead also presented additional data for Biktarvy which included findings from a 144-week analysis of the same Phase III studies.

This demonstrated that people living with HIV who received initial therapy with Biktarvy reached and maintained an undetectable viral load with no-treatment emergent resistance through 144 weeks.

A subgroup analysis of participants with transmitted-drug resistance (TDR) – based on a retrospective sequencing of baseline samples – found that Biktarvy achieved comparably high levels of durable viral suppression through 144 weeks among participants with and without TDR.

“Gilead is committed to developing innovative HIV treatments, like Biktarvy, that help to address the unmet needs of people living with HIV today, including achieving and maintaining an undetectable viral load over the long-term,” said Diana Brainard, senior vice president, virology therapeutic area, Gilead Sciences.

“These data reinforce that Biktarvy provides durable viral suppression, strong efficacy and a high barrier to resistance in both adults that are new to HIV therapy and those replacing their existing treatment,” she added.



Source link

Latest Articles

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...

Understand Key Account Management

INTRODUCTION: Key Account Management is the essential showcasing approach that gives a successful, useful, and rather basic technique for...

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...